MedTrace Logo

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

NCT07236190 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-22

No results posted yet for this study

Summary

This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology

Conditions

  • Alzheimer Disease
  • Mild Cognitive Impairment (MCI)
  • Subjective Cognitive Decline (SCD)

Interventions

COMBINATION_PRODUCT

natural product combination-1 (NPC1)

parthenolide plus ipriflavone

Sponsors & Collaborators

Principal Investigators

  • Gene Bowman, ND, MPH · Harvard/Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07236190 on ClinicalTrials.gov